Smaller-scale trades involved Pacific Biosciences of California Inc (NASDAQ: PACB) and 10X Genomics Inc (NASDAQ: TXG ), with ARK purchasing 194,298 and 18,177 shares respectively, totaling $213,727 ...

Shares of Vertex Pharmaceuticals Inc. plunged 10.03% to $450.03 Tuesday, on what proved to be an all-around grim trading ...

Giovinazzo is a Non-Executive Chairman at XORTX Therapeutics, Inc., an Executive Chairman at Kalgene Pharmaceuticals, Inc. and a Member at Institute of Corporate Directors. He is on the Board of ...

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 ...

Viking Therapeutics (NASDAQ ... to the same period in 2024," the company said in a statement. The company's stock is down about 1% after the bell.

VKTX Price Action: According to data from Benzinga Pro, Viking Therapeutics stock was down 1.12% after hours at $25.50 on Wednesday.

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

Cardiol Therapeutics CRDL is among the few companies evaluating an investigational cannabidiol (CBD) drug in late-stage development. This Canada-based company is developing an oral CBD-based ...

In this article, we are going to take a look at where Sarepta Therapeutics ... We first sifted through the Finviz stock screener and financial media reports to compile a list of the top stocks ...

With the firm’s Outperform rating, William Blair signals its confidence in Context Therapeutics’ potential to succeed within this innovative space. The stock has experienced significant volatility, ...